SİNAN DEMİRCİOĞLU, Ali DOĞAN, ÖMER EKİNCİ, CENGİZ DEMİR

The Association of NLR and MPV with Treatment Responses, Disease Stages, and International Prognostic Index Scores in Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. International Prognostic Index (IPI) is the most commonly used scoring system predicting the prognosis. In this study, we aimed to investigate the association of Neutrophil/Lymphocyte Ratio (NLR) and Mean Platelet Volume (MPV) with IPI score, treatment responses, and disease stage. A total of 113 DLBCL patients who received R-CHOP treatment were recruited for this study. Demographic data, disease stages according to the Ann Arbor staging system, IPI scores, treatment methods, treatment responses, complete blood counts, and biochemical tests of the patients were retrospectively evaluated. Elevated NLR had statistically significant correlation with disease stage and IPI score (p=0.001 and p=0.006, respectively). However, the NLR had no statistically significant correlation with the interim-treatment and post-treatment responses (p=0.187, and p=0.96, respectively). MPV showed no significant relationship with disease stages (p=0.56), IPI scores (p=0.188), interim-treatment and post-treatment responses (p=0.122, and p=0.239). In conclusion, NLR was associated with IPI score and disease stage. This suggests that NLR, a cheap and easy investigation, may be used to obtain information about the prognosis.

PDF

___

1. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010; 102: 83-87.

2. Ni J, Wang YQ, Zhang YP, et al. [Value of Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio for Prognostic Evaluation of Diffuse Large B-cell Lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2016; 24: 427-432.

3. Ho CL, Lu CS, Chen JH, Chen YG, Huang TC, Wu YY. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era. Medicine (Baltimore) 2015; 94: e993.

4. Cox MC, Nofroni I, Laverde G, et al. Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. British journal of haematology 2008; 141: 265-268.

5. Cox MC, Nofroni I, Ruco L, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leukemia & lymphoma 2008; 49: 1745-1751.

6. Oki Y, Yamamoto K, Kato H, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. European journal of haematology 2008; 81: 448- 453.

7. Kim DH, Baek JH, Chae YS, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007; 21: 2227-2230.

8. Schmidt H, Bastholt L, Geertsen P, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. British journal of cancer 2005; 93: 273-278.

9. Mohri Y, Tanaka K, Ohi M, Yokoe T, Miki C, Kusunoki M. Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World journal of surgery 2010; 34: 285- 290.

10. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181-184.

11. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007; 73: 215-220.

12. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009; 137: 425-428.

13. Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. American journal of hematology 2010; 85: 896-899.

14. Rupa-Matysek J, Gil L, Kroll-Balcerzak R, Baranska M, Komarnicki M. Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B-cell lymphoma. Hematological oncology 2017; 35: 456-464.

15. Zhou S, Ma Y, Shi Y, Tang L, Zheng Z, Fang F, et al. Mean platelet volume predicts prognosis in patients with diffuse large B-cell lymphoma. Hematological oncology 2018; 36: 104-109.

16. Riedl J, Kaider A, Reitter EM, Marosi C, Jager U, Schwarzinger I, et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS). Thromb Haemost 2014; 111: 670-678.

17. Zhuang Q, Xiang L, Xu H, et al. The independent association of mean platelet volume with overall survival in multiple myeloma. Oncotarget 2016; 7: 62640-62646.